MXC: $0.073
A Brief History of MGC Pharma

In May 2015, MGC Global was listed on the ASX following a reverse takeover deal with former gold explorer company, Erin Resources. Two years later, and MGC has undertaken groundbreaking research, come to strategic agreements with leading academia around the world and global companies, developed the highest quality products for our patients and and created our own premium Dermatological Cosmetic Cannabidiol Company. Discover MGC’s remarkable and forging history below.

Oct 2017

$40 Million White-Label CBD Cosmetics Agreement Executed

June 2017

First European Distribution deal signed for API products

June 2017

EU Medical Cannabis License granted with Strategic Agreement

May 2017

Strategic exclusive Agreement Signed with RMIT University to study the effects of Medical Cannabis on melanoma and other cancers.

May 2017

New CEO appointment of Roby Zomer

May 2017

New EU Sales Agreements Signed For MGC Derma

April 2017

European API Extraction Facility Completed

February 2017

MGC Pharmaceuticals Ltd acquired an 80% share of Czech Medical Cannabis company Panax Pharma s.r.o with option to buy remaining 20% share.

February 2017

Australian Legislation Changed Fast Track MXC

January 2017

Dermatological Clinical Trials Commenced

January 2017

European CPNP Approval Granted for Derma Products

December 2016

First Major European Sales and Revenue for MGC Derma Range

November 2016

EU Registration Commenced for CBD Derma Product Sales

September 2016

New Medical Cannabis White Paper Developed with University of Sydney

September 2016

Strategic Agreement signed with Epilepsy Action Australia

May 2016

Clinical study on children and adolescents with treatment-resistant epilepsy at Ljubljana University Medical Centre (Ljubljana UMC)  Efficacy study to test MGC Pharmaceuticals’ medicinal Cannabis formulation. Compares MXC proprietary whole plant extract based medicine with high CBD/THC ratio to pure synthetic CBD.

May 2016

An outdoor growing and extraction facility was established by  MGC Pharmaceuticals Ltd. in Slovenia in partnership with research and development business, Natura Laboratories Ltd. to develop high quality products for the cosmetics and pharmaceutical industries.

May 2016

Health Canada Approved MGC Derma CBD Cosmetics

May 2016

FDA Approval Granted and First US Distribution Deal Signed

May 2016

European Commission Approves MGC Derma Cosmetics Products

May 2016

MGC Pharmaceuticals Ltd. executed a binding of heads of Agreement (HOA) to acquire Czech- based Medical Cannabis company, PANAX Pharma s.r.o. (Panax) which enabled indoor operations via the Vukoz Institute research facility

April 2016

Launch of Online Store, www.mgcderma.com – First Retail Sales of CBD Cosmetics Recorded.

April 2016

MXC to Acquire Licensed European Medical Cannabis Company

March 2016

MXC Secured First Cosmetics Sales Agreement

March 2016

MXC Publishes First Australian Medical Cannabis White Paper

March 2016

MGC Pharmaceuticals Ltd. (ASX:MXC) took the first step into the world of pharmaceuticals, following research out of the Hadassah Medical Centre in Israel. An R&D agreement was developed with Israeli company, Sipnose, to develop technology which can transport  pharmaceuticals directly to the brain.

February 2016

Acquisition of MGC Pharma (UK) by MGC Pharmaceuticals Ltd.

December 2015

Change of Company Name to MGC Pharmaceuticals Ltd, formerly known as Erin Resources Limited.

May 2015

MGC Global was listed on the ASX following a reverse takeover deal with former gold explorer company, Erin Resources.